Institute for Cancer Research

Kjetil Taskén
Institute head

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 380 employees. About 70% of the employees and projects are externally funded. Read more

See introductory video with welcome to the ICR 

See full video covering all of ICR and its Departments 

Publication overview

Annual reports

Current news and events

Nature Communications article from Raiborg project group:Cancer cells transfer their invasive properties to non-invasive cells

Eva WenzelFirst author
Eva Wenzel
First author

Cancer cells degrade and invade their surrounding tissue by use of the enzyme MT1-MMP, which is expressed on their cell surface. In a new article published in Nature Communications on February 10, 2024, Eva Wenzel and her co-workers in Camilla Raiborg’s project group identify a new mechanism for cancer cell invasion, namely that cancer cells can transfer their invasive properties to non-invasive cells. They show how invasive cancer cells secrete catalytically active soluble forms of MT1-MMP, which dock on the surface of other cells. This enables non-invasive recipient cells to degrade and invade into the extracellular matrix, by use of the newly acquired MT1-MMP enzyme. 

Publication in Science:Treatment-induced resistance mutations in BTK can be overcome by a clinical-stage BTK degrader

Sigrid S. Skånland
Sigrid S. Skånland

Sigrid S. Skånland, project group leader at Department of Cancer Immunology, did a research stay at Memorial Sloan Kettering Cancer Center in New York in 2022. The work she did while she was in the group of Dr. Omar Abdel-Wahab has now been published in Science.

Bruton’s tyrosine kinase (BTK) inhibitors are used to treat the B-cell malignancy chronic lymphocytic leukemia (CLL). Resistance mutations to the first generation of inhibitors are well characterized and have formed the rationale for a new generation of inhibitors. However, also these lead to alterations in BTK over time.

Announcement: nominate a scientist for the 2024 OUH research awardsExcellent Researcher Award and Early Career Award

2023 award winners. From left: Kushtrim Kryeziu, Bente Halvorsen and Håvard Ole Skjerven
2023 award winners. From left: Kushtrim Kryeziu, Bente Halvorsen and Håvard Ole Skjerven

Oslo University Hospital hereby announce research awards in the following two catagories for 2024:

  • Excellent Researcher Award (one prize, 400.000 NOK)
  • Early Career Award (two prizes of 200.000 NOK each)

Closing date for nominations: March 6th 2024.

 

Mother collecting money for supporting precision warfare against cancer cells led by Johanna Olweus

Johanna Olweus
Johanna Olweus

20-year-old Victor Dyreng asked his mother to raise money for cancer research before he died of acute lymphoblastic leukemia (ALL) in February 2023. The mother is now collecting money for the research of Professor Johanna Olweus at the Department for Cancer Immunology at Oslo University Hospital.
Olweus is working on a new type of immunotherapy where immune cells are equipped with "heat-seeking missiles" to find and kill cancer cells. The researchers hope to start testing the treatment on humans during 2025.
The story is covered in a feature article in national newspaper VG.

Oslo University Hospital has awarded 6 excellent articles for the first half-year of 2023

Award winners
Award winners

In order to stimulate excellent research and draw attention to the hospital's research activity, Oslo University Hospital rewards outstanding publications every half-year.

Six research groups were awarded for their excellent papers published the first half-year of 2023 during a ceremony on December 8th.  Each group received NOK 50.000 earmarked for further research, and the prize winners gave short presentations of their main findings.